Trial Profile
Phase I Study of Adoptive Immunotherapy Using the Natural Killer Cell Line, Neukoplast™(NK-92), for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Mar 2021
Price :
$35
*
At a glance
- Drugs Natural killer cell therapy (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors ImmunityBio
- 27 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 27 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 06 Dec 2016 Status changed from active, no longer recruiting to completed, according to results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.